Our findings here suggest two major points: 1) the GPC1+ plasma exosome is a marker for the relapse in patients with stage III CRC, and 2) clinical management of relapse should be started before ninth months after surgery through measuring GPC1+ plasma exosomes. Here, GPC1 is linked to colorectal carcinoma.